摘要
目的:探讨强化阿托伐他汀对不稳定型心绞痛的有效性和安全性。方法:将80例不稳定性心绞痛患者随机分为两组,治疗组常规治疗加上阿托伐他汀40mg/d,对照加用阿托伐他汀20mg/d。两组均在治疗前及治疗6个月后测定血脂四项、C反应蛋白水平,观察不良心血管事件及不良反应事件的发生情况。结果:治疗6个月后,两组血脂和C反应蛋白水平有不同程度的降低,与对照组比较,治疗组降低更显著(P<0.05);治疗组患者心血管不良事件发生率更低(P<0.05);两组不良反应事件发生率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀强化治疗能改善不稳定型心绞痛患者的预后,在权衡患者药物使用利弊后,推荐40mg/d强化治疗。
Objective： To investigate the influence of different doses of atorvastatin in the prognosis of unstable angina.Methods： 80 cases of patients treated with unstable angina were randomly divided into two groups.In the control groups, 40 patients accepted conventional treatments and Atorvastatin 20 mg daily, while in the treatment groups 40 patients accepted conventional treatment and Atorvastatin 40 mg daily.Both groups were measured before and after 180d treatment at the four lipids, CRP, and were observed of Re-angina, myocardial infarction and cardiac death and other undesirable occurrence of cardiovascular events.Results ： The lipid levels of two groups had varying degrees of reduction after treatment.Compared with the control group, the observation group was more obvious（P〈0.05）.The two groups both reduce CRP level after treatment.Compared with the control group, the effect of the observation group was more obvious（P〈0.05）.With the occurrence of adverse events, the diffierence was not statistically significant between two groups（P〉0.05）.Conclusion： Atorvastatin intensive treatment can improve the prognosis of patients with unstable angina and intensive treatment after weigh in patients with drug use pros and cons, recommended 40 mg/d.
出处
《中外医学研究》
2013年第7期5-6,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
